Anavex Presents Preclinical Results of ANAVEX 2-73 in Rett Syndrome

– Data presentation at 2016 Epilepsy Pipeline Conference – – Company exploring potential to advance ANAVEX 2-73 into human clinical studies in rare disease indication – NEW YORK, NY – February 25, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of…